Physician profile
David Todd Asher
NPI 1275578304
$7,478.28
in general payments reported to CMS, 2019-2025
31 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,532 · 2020: $1,209 · 2021: $1,306 · 2022: $1,737 · 2023: $269 · 2024: $225 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $695.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $695.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Uswm, LLC | $1,098.73 | 2021-2024 | Lucemyra, Zimhi |
| Astrazeneca Pharmaceuticals Lp | $730.49 | 2019-2022 | |
| Lilly USA, LLC | $696.92 | 2019-2023 | Mounjaro, Jardiance |
| Pfizer INC. | $588.47 | 2019-2021 | |
| Alkermes, INC. | $437.31 | 2019-2023 | Vivitrol |
| Abbvie INC. | $406.73 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $360.45 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.49 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $355.41 | 2019-2024 | Invega Sustenna, Invega Trinza |
| Eisai INC. | $309.22 | 2020-2022 | |
| Mdd US Operations, LLC | $297.48 | 2019-2020 | |
| Allergan, INC. | $284.26 | 2019-2022 | |
| Braeburn INC. | $264.30 | 2024-2025 | Brixadi |
| Indivior INC. | $222.02 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $213.24 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $211.02 | 2019-2023 | Wegovy |
| Almatica Pharma LLC | $117.20 | 2021-2023 | Citalopram, Loreev Xr, Sertraline Hcl |
| Orexo US, INC. | $96.78 | 2019-2021 | |
| Gilead Sciences, INC. | $80.43 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $62.86 | 2022-2025 | Caplyta |
| Kaleo, INC. | $57.09 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $47.16 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $35.89 | 2020 | |
| Neuronetics, INC. | $32.85 | 2019 | |
| Sanofi Pasteur INC. | $25.67 | 2019 | |
| Exact Sciences Corporation | $18.20 | 2025 | Cologuard Collection Kit |
| Organon LLC | $17.44 | 2025 | Nexplanon |
| Takeda Pharmaceuticals U.S.A., INC. | $15.53 | 2021 | |
| Lundbeck LLC | $14.70 | 2020 | |
| Idorsia Pharmaceuticals US INC | $12.99 | 2022 | |
| Titan Pharmaceuticals, INC. | $11.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Asher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.